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BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation
carriers has been shown to decrease with longer duration of oral con-
traceptive use. Although the effects of using oral contraceptives in the
general population are well established (approximately 50% risk reduction
in ovarian cancer), the estimated risk reduction in mutation carriers is
much less precise because of potential bias and small sample sizes. In
addition, only a few studies on oral contraceptive use have examined the
associations of duration of use, time since last use, starting age, and
calendar year of start with risk of ovarian cancer.
OBJECTIVE: This study aimed to investigate in more detail the asso-
ciations of various characteristics of oral contraceptive use and risk of
ovarian cancer, to provide healthcare providers and carriers with better
risk estimates.
STUDYDESIGN: In this international retrospective study, ovarian cancer
risk associations were assessed using oral contraceptives data on 3989
BRCA1 and 2445 BRCA2mutation carriers. Age-dependenteweighted Cox
regression analyses were stratified by study and birth cohort and included
breast cancer diagnosis as a covariate. To minimize survival bias, analyses
were left truncated at 5 years before baseline questionnaire. Separate an-
alyses were conducted for each aspect of oral contraceptive use and in a
multivariate analysis, including all these aspects. In addition, the analysis of
duration of oral contraceptive use was stratified by recency of use.
RESULTS: Oral contraceptives were less often used by mutation carriers
who were diagnosed with ovarian cancer (ever use: 58.6% for BRCA1 and
53.5% BRCA2) than by unaffected carriers (ever use: 88.9% for BRCA1
and 80.7% for BRCA2). The median duration of use was 7 years for both
BRCA1 and BRCA2 carriers who developed ovarian cancer and 9 and 8
years for unaffected BRCA1 and BRCA2 carriers with ovarian cancer,
respectively. For BRCA1mutation carriers, univariate analyses have shown
that both a longer duration of oral contraceptive use and more recent oral
contraceptive use were associated with a reduction in the risk of ovarian
cancer. However, in multivariate analyses, including duration of use, age at
first use, and time since last use, duration of oral contraceptive use proved
to be the prominent protective factor (compared with<5 years: 5e9 years
[hazard ratio, 0.67; 95% confidence interval, 0.40e1.12]; >10 years
[hazard ratio, 0.37; 95% confidence interval, 0.19e0.73]; Ptrend¼.008).
The inverse association between duration of use and ovarian cancer risk
persisted for more than 15 years (duration of 10 years; BRCA1 <15
years since last use [hazard ratio, 0.24; 95% confidence interval,
0.14e0.43]; BRCA1 >15 years since last use [hazard ratio, 0.56; 95%
confidence interval, 0.18e0.59]). Univariate results for BRCA2 mutation
carriers were similar but were inconclusive because of limited sample size.
CONCLUSION: For BRCA1 mutation carriers, longer duration of oral
contraceptive use is associated with a greater reduction in ovarian cancer
risk, and the protection is long term.
Key words: BRCA1, BRCA2, epidemiology, multivariate, observational,
oral contraceptives, ovarian cancer, retrospective, risk, survival bias
Introduction
Mutations in the BRCA1 and BRCA2
genes are associated with a high lifetime
risk of ovarian cancer. The average cu-
mulative risk of ovarian cancer up to the
age of 70 years has been estimated to be
41% (95% confidence interval [CI],
33e50) for BRCA1mutation carriers and
15% (95% CI, 10e23) for BRCA2 muta-
tion carriers.1 The use of oral
contraceptives is a strong protective factor
(approximately 50%, with a dose-
response association observed with dura-
tion of use) for ovarian cancer in the
general population and has been sug-
gested as chemoprevention for BRCA1
and BRCA2 mutation carriers.2e5
Although the effects of using oral con-
traceptives in the general population are
well established, the estimated risk
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reduction in mutation carriers is much
less certain and precise because of poten-
tial bias and small sample sizes. All pre-
vious studies were retrospective and
therefore susceptible to survival bias. Only
1 study, as a sensitivity analysis, mini-
mized potential survival bias by restricting
the analyses to person-years within the 3
years before study enrollment.6 So far,
almost all previous BRCA1 and BRCA2
mutation carrier studies restricted ana-
lyses to risk of ovarian cancer and dura-
tion of use of oral contraceptives.
To provide carriers with better risk
estimates, we wanted to investigate in
more detail the association between oral
contraceptive use and risk of ovarian
cancer. We used retrospective data from
the International BRCA1/2 Carrier
Cohort Study (IBCCS). Here, we were
able to mutually adjust for multiple
characteristics of oral contraceptive use
to better understand their associations
with ovarian cancer risk. To minimize
the potential for survival bias, we used a
left-truncated approach and conducted
full-cohort retrospective analyses (ie,




The IBCCS is a collaborative European
study of women carrying a pathogenic or
likely pathogenic germline mutation in
BRCA1 or BRCA2. Women were eligible
if they were between 18 and 80 years of
age at recruitment. More than two-thirds
of participants were enrolled to 1 of the 3
large ongoing nationwide studies in the
United Kingdom and Ireland (Epide-
miologic Study of Familial Breast Can-
cer), France (Gene Etude Prospective
Sein Ovaire), and the Netherlands (He-
reditary Breast and Ovarian Cancer
Research, Netherlands).7 For the current
analyses, women with both BRCA1 and
BRCA2 mutations were excluded. In
addition, women born before 1920 were
excluded, because their reproductive
years preceded the availability of oral
contraceptives.
Data collection
A baseline questionnaire elicited detailed
information on known or suspected risk
factors for breast and ovarian cancer.
Data on preventive surgeries and cancer
occurrence were collected from medical
records or linkages to cancer and pa-
thology registries (75%) or question-
naires (25%). Participants provided
written informed consent, and each
study was approved by the relevant
institutional ethical committee.
Statistical analysis
To estimate hazard ratios (HRs), time-
dependent Cox proportional hazards
regression models with age as the time-
scale were used, stratified for birth
cohort and study. To reduce the possible
impact of survival bias, analyses were left
truncated, restricting the analyses to
person-years within 5 years before study
enrollment (age at baseline question-
naire). This implies that we started
follow-up 5 years before baseline, with
women at risk of developing ovarian
cancer (so at least 1 ovary in situ: BRCA1
[n¼3989] and BRCA2 [n¼2445]). For
those, who were diagnosed with ovarian
cancer during the next 5 years, the mean
survival was 3.2 years for BRCA1 muta-
tion carriers and 2.9 years for BRCA2
mutation carriers, ranging from 0 to 5
years. Person-years were calculated up to
the diagnosis of ovarian cancer (event of
interest), diagnosis of another cancer
(with the exception of breast cancer and
nonmelanoma skin cancer), risk-
reducing salpingo-oophorectomy
(RRSO), mutation testing, or baseline
questionnaire completion, whichever
came first. Because of the retrospective
nature of the study and because only
person-years before DNA test was
included, womenwere not aware of their
mutation during the ages, the person-
years, included for analysis. Breast can-
cer diagnosis was included as a time-
dependent covariate. To correct for the
potential testing bias, analyses were
performed using the extended weighted
regression approach described by Anto-
niou et al.8,9 Cancer cases are more often
genetically tested on unaffected women.
Therefore, the cancer incidence in a
retrospective cohort of mutation carriers
is overestimated, and the estimated HRs
are underestimated. To correct for this
testing bias, ovarian and breast cancer
cases and unaffected women were
weighted differentially to ensure that
age-specific incidence rates implied by
AJOG at a Glance
Why was this study conducted?
The use of combined oral contraceptives is a strong protective factor for ovarian
cancer and has been suggested as chemoprevention for BRCA1 and BRCA2
mutation carriers. Previous studies on oral contraceptive use were limited in
sample size, and other than duration of use, only a few studies have examined the
other characteristics of oral contraceptive use.
Key findings
For BRCA1 mutation carriers, longer duration of oral contraceptive use is asso-
ciated with a reduction in ovarian cancer risk, and the protection is long term.
Findings for BRCA2 mutation carriers were similar but less definitive given the
smaller sample size.
What does this add to what is known?
To date, most studies have examined the association of duration of oral contra-
ceptive use with risk of ovarian cancer, without taking other characteristics of oral
contraceptive use into account. For BRCA1mutation carriers, we have shown that
the duration of oral contraceptive use is indeed more important than recency of
use or starting age. Moreover, the strong protective effect of long duration of oral
contraceptive use persists for a long period. Current results are based on a rela-
tively large sample of BRCA1 and BRCA2 mutation carriers and corrected for
potential testing and survival biases.
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the weighted cohort were consistent with
known incidence rates for women with a
BRCA1 or BRCA2 mutation. Carriers
who developed breast or ovarian cancer
were underweighted (weights <1), and
the unaffected carriers were over-
weighted (weights >1). In general, the
unweighted HR estimates were closer to
the null value than the weighted HRs,
and the 95% CIs are narrower. For
instance, forever vs never use un-
weighted HRs were 0.72 (95% CI,
0.58e0.90) for BRCA1 and 0.80 (95%
CI, 0.55e1.17) for BRCA2 mutation
carriers, compared with the weighted
HRs of 51 (95% CI, 0.36e0.71) and 0.65
(95% CI, 0.35e1.19) for BRCA1 and
BRCA2 mutation carriers.
The effect of familial clustering on
estimates of precision was accounted for
using robust variance estimation. Trend
tests were based on modeling the
category-specific mean as a continuous
variable. We conducted a separate anal-
ysis for duration of use, time since last
use, and starting age (“oral contraceptive
univariate”) and a multivariate analysis,
including all of these aspects of oral
contraceptive use (“oral contraceptive
multivariate”). In addition, the analysis
of duration of oral contraceptive use was
stratified by recency of use. All charac-
teristics of oral contraceptive use were
considered time-dependent covariates,
computed for each year of observation.
None of the potential confounders
(family history, parity number of preg-
nancies, and menopausal status)
changed the HRs for oral contraceptive
use and ovarian cancer risk bymore than
10%, and therefore, they were excluded
from the final models.
Sensitivity analyses were composed of
the following: (1) stratified analyses
(birth cohort, study, and attained age),
(2) left-truncated analyses censored for
breast cancer diagnosis, (3) multiple
imputations for missing covariate data,
and (4) multiple imputations with a
random-effects Cox model approach,
where we considered study site as a
random term.10 Covariates were
imputed 50 times in 5 iterations. Cova-
riates were imputed with multivariate
imputation by changed equations, using
conditional multiple imputations that
follow an iterative procedure. Further-
more, we conducted “full-cohort”
retrospective analyses, where the analysis
included person-years from birth
instead of being left truncated.
All statistical tests were two-sided and
a P value of <.05 was considered statis-
tically significant. Trend tests were based
on the P value for the continuous vari-
able based on fitting category-specific
means. Analyses were performed using
Stata (version 13; StataCorp, College
Station, TX), except for the multiple
imputations andmixedmodel sensitivity
analyses for which R (version 4.0.2; R
Foundation, Vienna, Austria) was used.
Results
In the left-truncated analyses of 3989
BRCA1 mutation carriers, 346 women
(8.7%) were diagnosed with ovarian
cancer at censoring (Table 1). Ovarian
cancer cases completed their question-
naire on average 1.8 years (range, 0e5
years) after their ovarian cancer diag-
nosis. Of the 3642 BRCA1 mutation
carriers (91.3%) who were unaffected by
ovarian cancer, 2.4% were censored at
age of RRSO. Of the 2445 BRCA2 mu-
tation carriers, 106 women (4.3%) were
diagnosed with ovarian cancer at
censoring. BRCA2 ovarian cancer cases
completed their questionnaire on
average 2.1 years (range, 0e5 years) after
their ovarian cancer diagnosis. Of the
2339 BRCA2 mutation carriers (95.6%)
who were unaffected with ovarian can-
cer, 1.8% were censored at age of RRSO.
For both BRCA1 and BRCA2 mutation
carriers, compared with ovarian cancer
cases, women unaffected with ovarian
cancer were younger (BRCA1, 40.5 vs
51.7 years; BRCA2, 43.4 vs 56.9 years)
and thus born more recently (birth year
1952e1980: 81.0% vs 43.4% for BRCA1
and 76.7% vs 29.3% for BRCA2). A
relatively large proportion was diag-
nosed with breast cancer before the end
of follow-up (BRCA1, 37.9% for those
affected with ovarian cancer and 37.9%
for those unaffected with ovarian cancer;
BRCA2, 33.0% for those affected ovarian
cancer and 37.7% for ovarian cancer
unaffected).
Oral contraceptives were less often
used by women who were diagnosed
with ovarian cancer (ever use: 58.6% for
BRCA1 and 53.5% for BRCA2) than by
unaffected carriers (ever use:88.9% for
BRCA1 and 80.7% for BRCA2) (Table 2).
The median duration of use was 7 years
for both BRCA1 and BRCA2 ovarian
cancer cases (interquartile rage (IQR):
3e11 years for BRCA1 and 4e12 years
for BRCA2) and 9 years (IQR, 5e13
years) and 8 years (IQR, 5e13 years) for
BRCA1 and BRCA2 mutation carriers
who were unaffected with ovarian can-
cer, respectively.
In univariate analyses, only 1 charac-
teristic of oral contraceptive use was
taken into account per analysis. Ever oral
contraceptive use was associated with a
reduction in the risk of ovarian cancer
for BRCA1 mutation carriers (HR, 0.51;
95% CI, 0.36e0.71) (Table 2). For
BRCA2 mutation carriers, the estimated
HR for ever oral contraceptive use and
ovarian cancer risk was comparable
(HR, 0.65; 95% CI, 0.35e1.19) but not
statistically significant. A longer dura-
tion of oral contraceptive use was asso-
ciated with a stronger risk reduction for
BRCA1 mutation carriers (HR, 0.92;
95% CI, 0.88e0.96; Ptrend<.001): HR of
0.79 (95% CI, 0.53e1.19), 0.54 (95% CI,
0.35e0.85), and 0.32 (95% CI,
0.21e0.50) for durations of <5 years,
5e9 years, and >10 years, respectively.
For BRCA2 mutation carriers, again HR
estimates were in the same direction, but
the associations were not significant
(Ptrend¼.45). For both BRCA1 and
BRCA2 mutation carriers, a strong pro-
tection was found during oral contra-
ceptive use and within 10 years of oral
contraceptive use (current use and <10
years ago [BRCA1 HR, 0.40 (95% CI,
0.22e0.71); BRCA2 HR, 0.36 (95% CI,
0.14e0.92)]; 10e19 years ago [BRCA1
HR, 0.54 (95% CI, 0.36e0.82); BRCA2
HR, 0.58 (95% CI, 0.24e1.42)]; 20
years ago [BRCA1 HR, 0.61 (95% CI,
0.43e0.87); BRCA2 HR, 0.78 (95% CI,
0.40e1.52)]; trend [BRCA1, P¼.025;
BRCA2, P¼.26]). For BRCA1 mutation
carriers, the association between ever use
of oral contraceptives and risk of ovarian
cancer did not show a clear trend ac-
cording to age at first use of oral con-
traceptives (19 years [HR, 0.43; 95%
CI, 0.28e0.65]; 20e23 years [HR, 0.51;
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TABLE 1
Characteristics of 3989 BRCA1 and 2445 BRCA2 mutation carriers in the left-truncated IBCCS cohort
Characteristics
BRCA1 mutation carriers BRCA2 mutation carriers
OvCaþ OvCa OvCaþ OvCa
N¼3989 N¼2445
n (%) 346 (8.7) 3643 (91.3) 106 (4.3) 2339 (95.7)
Mean age at start of follow-up (SD), y 48.4 (8.9) 36.4 (11.5) 54.0 (9.1) 39.0 (11.8)
Mean age at end of follow-up (SD), y 51.7 (8.9) 40.5 (11.4) 56.9 (9.1) 43.4 (11.7)
Age at end of follow-up, y
<37 14 (4.1) 1413 (38.8) 4 (3.8) 696 (29.8)
37e46 89 (25.7) 1202 (33.0) 8 (8.6) 771 (33.0)
>47 243 (70.2) 1028 (28.2) 94 (88.7) 872 (37.3)
Mean person-years (y/person) (SD) 3.2 (1.2) 4.2 (1.2) 2.9 (1.2) 4.4 (1.1)
Censored for the following:
Ovarian cancer 346 (100.0) 0 (0.0) 106 (100.0) 0 (0.0)
DNA test or baseline questionnaire 0 (0.0) 3521 (96.6) 0 (0.0) 2273 (97.2)
Other cancer 0 (0.0) 41 (1.1) 0 (0.0) 29 (1.2)
Bilateral RRSO 0 (0.0) 81 (2.2) 0 (0.0) 37 (1.6)
Year at end of follow-up
1990e2000 137 (39.6) 1122 (30.8) 33 (31.1) 370 (15.8)
2001e2005 133 (38.4) 1354 (37.2) 42 (39.6) 976 (41.7)
2006e2012 76 (22.0) 1167 (32.0) 31 (29.3) 993 (42.5)
Birth year
1920e1944 87 (25.1) 292 (8.0) 55 (51.9) 236 (10.1)
1945e1951 109 (31.5) 401 (11.0) 20 (18.9) 308 (13.2)
1952e1980 150 (43.4) 2950 (81.0) 31 (29.3) 1795 (76.7)
Studya
EMBRACE 129 (9.8) 1183 (90.2) 64 (5.5) 1095 (94.5)
GENEPSO 64 (6.9) 865 (93.1) 15 (2.7) 546 (97.3)
Otherb 153 (8.8) 1595 (91.3) 27 (3.7) 698 (96.3)































95% CI, 0.33e0.78]; >24 years [HR,
0.63; 95% CI, 0.41e0.97]; Ptrend¼.15).
Calendar year of first use did not modify
the HR for ever use for BRCA1 and
BRCA2 mutation carriers.
Age at first use, duration of use, and
time since last use of oral contraceptives
are closely related. For instance, at
censoring, the average duration of use of
oral contraceptives was longer for recent
users than for those who stopped a long
time ago (BRCA1: 115.8 years for
recent users vs 53.4 years for those who
stopped >20 years ago). In addition,
BRCA1 mutation carriers used oral
contraceptives for a longer duration
when they had started at a younger age.
For ages at first oral contraceptive used
19 years or 24 years, mean durations
of use were 10 (5.6) and 7 (5.9) years,
respectively. Therefore, we conducted
multivariate analyses, including dura-
tion of use, time since last use, and age at
first use of oral contraceptives in the
same model. In this model, only dura-
tion of use of oral contraceptives
remained independently associated with
ovarian cancer risk (<5 years [reference,
5e9 years; HR, 0.67; 95% CI,
0.40e1.12]; 10 years [HR, 0.37; 95%
CI, 0.19e0.73]; Ptrend¼.008) for BRCA1
mutation carriers. The sample size was
too limited to perform comparable
multivariate analysis for BRCA2 muta-
tion carriers.
Analyses on the duration of use of oral
contraceptives stratified by time since
last use (Table 3) showed that the inverse
association between duration of use and
ovarian cancer risk persisted for a long
period (15 years). It seemed that the
association for long-term users (10
years of use) was somewhat stronger in
more recent years (<15 years since use)
after oral contraceptive use (BRCA1:
<15 years since last use [HR, 0.24; 95%
CI, 0.14e0.43]; >15 years since last use
[HR, 0.56; 95% CI, 0.18e0.59]); how-
ever, this interaction was not statistically
significant. The finding for attained age
was consistent with findings for time
since last oral contraceptive use. A sig-
nificant inverse association with dura-
tion of oral contraceptive use was
observed only for BRCA1 mutation car-
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TABLE 2
The oral contraceptive “univariate” association between aspects of oral contraceptive use and risk of ovarian cancer for 3989 BRCA1 and 2445 BRCA2
mutation carriers
Variable
BRCA1 mutation carriers BRCA2 mutation carriers
OvCaþ, n (%)c OvCa, n (%)c Weighted,a,b HR (95% CI)d OvCaþ, n (%)c OvCa, n (%)c Weighted,a,b HR (95% CI)e
Oral contraceptive use
Never (<6 mo) 133 (41.4) 659 (19.1) 1.00 46 (46.5) 426 (19.3) 1.00
Ever 188 (58.6) 2788 (88.9) 0.51 (0.36e0.71) 53 (53.5) 1782 (80.7) 0.65 (0.35e1.19)
Ever, starting age unknown 11 125 4 87
Missing 14 71 3 44
Calendar year at start
Never (<6 mo) 133 (41.4) 659 (19.1) 1.00 46 (46.5) 426 (19.3) 1.00
1975 114 (35.5) 684 (19.8) 0.45 (0.33e0.62) 39 (39.4) 492 (22.3) 0.73 (0.38e1.39)
>1975 74 (23.1) 2104 (61.0) 0.56 (0.35e0.88) 14 (14.1) 1290 (58.4) 0.49 (0.23e1.05)
Ever, starting year unknown 11 125 4 87
Missing 14 71 3 44
Total duration of use
Never (<6 mo) 133 (43.0) 659 (20.2) 1.00 46 (47.4) 426 (20.4) 1.00
<5 y 67 (21.7) 616 (18.9) 0.79 (0.53e1.19) 17 (17.5) 401 (19.2) 0.87 (0.42e1.80)
5e9 y 53 (17.2) 867 (26.6) 0.54 (0.35e0.85) 13 (13.4) 557 (26.6) 0.51 (0.23e1.12)
10 y 56 (18.2) 1121 (34.4) 0.32 (0.21e0.50) 21 (21.7) 707 (33.8) 0.60 (0.28e1.27)
Ever, no period specific data 23 309 6 204
Missing 14 71 3 44
Trendf P¼2.0E-04 P¼.449
Time since last use
Never (<6 mo) 133 (43.0) 659 (20.2) 1.00 46 (47.4) 426 (20.4) 1.00
<10 y 29 (9.4) 1478 (45.3) 0.40 (0.22e0.71) 7 (7.2) 825 (39.5) 0.36 (0.14e0.92)
10e19 y 60 (19.4) 648 (19.9) 0.54 (0.36e0.82) 12 (12.4) 415 (19.9) 0.58 (0.24e1.42)
20 y 87 (28.2) 478 (14.7) 0.61 (0.43e0.87) 32 (33.0) 425 (20.3) 0.78 (0.40e1.52)
Ever, no period specific data 23 309 6 204
Missing 14 71 3 44
Trendf P¼.025 P¼.258































Table 1). However, the difference in the
effect sizes was not significant.
Analyses stratified for birth cohort
(univariate, unweighted) suggested that
the significant inverse association be-
tween duration of use and ovarian can-
cer risk was limited to more recent birth
cohorts (1920e1946 [P¼.144];
1947e1954 [P¼.373]; 1955e1980
[P¼.009]; data not shown). Sample size
was limited to examine if this could be
explained by recency of use.
Study-specific analyses (univariate,
unweighted, data not shown) have
shown that for BRCA1 mutation car-
riers, the association between ever use
and ovarian cancer risk was comparable
for all studies (HR estimates varied be-
tween 0.43 and 0.82). For BRCA2 mu-
tation carriers, sample size was too
limited to stratify for study.
In the analyses of oral contraceptive
use and ovarian cancer risk, we included
women with a personal history of breast
cancer, treating breast cancer as a time-
dependent covariate. To further explore
the impact of a potential association
between oral contraceptive use and risk
of breast cancer in these analyses, we
censored for breast cancer diagnosis in a
sensitivity analysis and thus excluded
women with a personal breast cancer
history. We found a virtually identical
inverse association between oral contra-
ceptive use and risk of ovarian cancer
(ever vs never: BRCA1 HR, 0.47 [95%
CI, 0.32e0.70]; BRCA2 HR, 0.57 [95%
CI, 0.27e1.19]).
Results of the multiple imputation
sensitivity analyses using the Cox model
with either fixed- or random-effects
agreed with our main results for dura-
tion of oral contraceptive use. For BRCA1
mutation carriers, a longer duration of
oral contraceptive use was associated with
a reduction in ovarian cancer risk (main
results [HR, 0.92; P<.001]; multiple
imputation fixed model [HR, 0.94;
P<.001]; multiple imputation random
model [HR, 0.94; P<.001]). For BRCA2
mutation carriers, no significant trend
was found for duration of oral contra-
ceptive use (main results [HR, 0.97;
P¼.45]; multiple imputation fixed model
[HR, 0.98; P¼.33]; multiple imputation
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TABLE 3
The associations of duration, recency, and starting use of oral contraceptives and risk of ovarian cancer for BRCA1
mutation carriers
Variable OvCaþ, n (%)a OvCa, n (%)a
Oral contraceptive





Oral contraceptive never use 133 (43.0) 659 (20.2) 1.15 (0.40e3.34)
Total duration of use, y
<5 67 (21.7) 616 (18.9) 1.00 1.00
5e9 53 (17.2) 867 (26.6) 0.69 (0.43e1.09) 0.67 (0.40e1.12)
10 56 (18.2) 1121 (34.4) 0.40 (0.25e0.65) 0.37 (0.19e0.73)
Trende P¼2.0E-04 P¼.008
Time since last use, y
<10 29 (9.4) 1478 (45.3) 1.00 1.00
10e19 60 (19.4) 648 (19.9) 1.35 (0.77e2.37) 0.96 (0.50e1.83)
20 87 (28.2) 478 (14.7) 1.50 (0.85e2.66) 0.79 (0.35e1.78)
Trende P¼.015 P¼.238
Starting age, y
19 58 (18.8) 1632 (50.0) 1.00 1.00
20e23 51 (16.5) 580 (17.8) 1.07 (0.68e1.70) 0.98 (0.61e1.58)
>23 67 (21.7) 392 (12.0) 1.51 (0.91e2.50) 1.15 (0.65e2.04)
Trende P¼.154 P¼.665
Ever, starting age unknown 23 309
Missing 14 71
Stratified for recency of use HR (95% CI)c
Total duration of use
Never (<6 mo) 133 (43.0) 659 (20.2) 1.00
<15 y since last use
<5 y 10 (3.2) 288 (8.8) 1.21 (0.55e2.68)
5e9 y 16 (5.2) 580 (17.8) 0.61 (0.30e1.24)
10 y 25 (8.1) 956 (29.3) 0.24 (0.14e0.43)
Trendc P¼2.2e-04
>15 y since last use
<5 y 57 (18.5) 328 (10.1) 0.72 (0.48e1.07)
5e9 y 37 (12.0) 287 (8.8) 0.47 (0.29e0.76)
10 y 31 (10.0) 165 (5.1) 0.56 (0.18e0.59)
Trendc P¼.374
Ever, no period specific data 23 309
Missing 14 71
BRCA, breast cancer gene; CI, confidence interval; EMBRACE, Epidemiological Study of Familial Breast Cancer; GENEPSO, Gene Etude Prospective Sein Ovaire; HR, hazard ratio; OvCa, ovarian
cancer.
a Distribution of variables at end of follow-up; b Weighted: to account for the oversampling of affected individuals (breast and ovarian cancer); c Intrinsically stratified on study (EMBRACE, GENEPSO,
other) and birth cohort (1920e1946, 1947e1954, 1955e1980). Clustered on family membership; d In addition: mutually adjusted for duration, time since, and age at start of oral contraceptive
use; e Trend tests were based on the P value of the category-specific mean as a continuous variable of ever oral contraceptive users.
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The full-cohort approach included
person-years from birth, adding 829
BRCA1 and 399 BRCA2 mutation car-
riers, where 209 and 68 of whom,
respectively, were diagnosed with
ovarian cancer. The average time be-
tween ovarian cancer diagnosis and
enrollment was 5.4 years (range, 0e36
years) for BRCA1 and 5.8 years (range,
0e30 years) for BRCA2 mutation car-
riers (19% were enrolled >10 years
following diagnosis). For both BRCA1
and BRCA2 mutation carriers, results of
full-cohort analyses were consistent, but
associations were slightly attenuated
compared with those from left-
truncated analyses (Supplemental
Table 2 and Supplemental Table 3).
Discussion
Principal findings
Based on data for 3989 BRCA1mutation
carriers, we found a clear inverse asso-
ciation between oral contraceptive use
and ovarian cancer risk. Whereas both a
longer duration and more recent use of
oral contraceptives showed greater in-
verse associations with risk of ovarian
cancer, duration of use was the promi-
nent protective factor in multivariate
analyses. The reduction with a longer
duration of oral contraceptive use was
still present more than 15 years after
stopping. For BRCA2 mutation carriers
(n¼2445), the HR estimates were
consistent, but CIs were wide.
Results in the context what is
already known
To date, 4 retrospective studies have
investigated the association between oral
contraceptive use and ovarian cancer
risk stratified by gene mutation,4,6,9,11
and only 1 conducted left-truncated
analyses. The study of McLaughlin
et al6 included a subset of the partici-
pants in Kotsopoulos et al4 and the study
of Antoniou et al9 included a subset of
the carriers included in this study. For
both BRCA1 and BRCA2 mutation car-
riers, 2 independent studies4,11 have re-
ported a stronger risk reduction with
longer duration of use of oral contra-
ceptives, but these authors did not
consider other aspects of oral contra-
ceptive use. Kotsopoulos et al4 found
strong risk reductions after short dura-
tions of use for both BRCA1 and BRCA2
mutation carriers (BRCA1, 1e<3 years
[odds ratio (OR), 0.56; 95% CI,
0.41e0.75]; BRCA2, 3e<5 years [OR,
0.42; 95% CI, 0.22e0.83]). In contrast,
we found modest, not significant, risk
reductions for less than 5 years of use
(HR, 0.79 [95% CI, 0.53e1.19] and 0.87
[95% CI, 0.42e1.80], respectively). For
BRCA2mutation carriers, we found only
a significantly reduced risk for a duration
of 5 to 9.99 years, but there was no evi-
dence for a trend (P¼.45). With the
exception of “ever use” and “duration of
use,” the oral contraceptive aspects “age
at start,” “calendar year at start,” and
“time since last use” were investigated
only by Antoniou et al,9 a subset of our
study. The study of Antoniou et al9
included 2281 BRCA1 mutation car-
riers, 201 diagnosed with ovarian cancer,
and 1038 BRCA2 mutation carriers, 52
diagnosed with ovarian cancer. In
both analyses, we found decreasing risks
of ovarian cancer with longer durations
or oral contraceptive use and more
recent oral contraceptive use for BRCA1
mutation carriers. However, in this
study, after mutual adjustment of these
related aspects of oral contraceptive use,
only duration of use remained signifi-
cantly associated with ovarian cancer
risk. The power of the previous study
was too limited to explore mutual
adjustments.
In the general population, oral con-
traceptive use is associated with a
reduced risk of ovarian cancer, and the
reduction in risk of ovarian cancer is
stronger for longer durations of oral
contraceptive use. In addition, relative
risks of ovarian cancer remained low for
a prolonged period after stopping oral
contraceptive use and only attenuated 20
years after stopping.12 In our BRCA1
analysis of duration of use within cate-
gories of recency of use, oral
contraceptiveeassociated risk re-
ductions persisted for a long period.
Whether the risk reduction attenuated
over time could not be confirmed for
BRCA1 mutation carriers but was not
ruled out. For BRCA2mutation carriers,
a similar analysis was not possible
because of the small sample size.
Clinical and research implications
Although oral contraceptive use might
be considered a preventive approach for
developing ovarian cancer, its use in
BRCA1 and BRCA2 mutation carriers
needs to be weighed against the possible
association of oral contraceptive use with
increased risk of breast cancer.13 How-
ever, the inverse association with ovarian
cancer is stronger than the possible
positive association with breast cancer
risk. The cumulative risk of breast cancer
is 43% (95% CI, 39e49; BRCA1) and
35% (95% CI, 29e41; BRCA2) at age 50
years, when the cumulative of ovarian
cancer is 8% (95% CI, 6e12; BRCA1)
and 0% (95% CI, 0e2; BRCA2).1
Consequently, in the years before
ovarian cancer incidence starts to rise for
mutation carriers, the beneficial effect of
oral contraceptive use on ovarian cancer
risk will likely not outweigh the potential
increased risk of oral contraceptive use
on breast cancer risk. In addition, in
many Western countries to date, most
BRCA1 and BRCA2 carriers (70%
e75%) opt for RRSO around age 40
years, when childbearing is
completed;14,15 however, the uptake of a
risk-reducing mastectomy is low (35%
e44%)16 and varies widely among
countries. In addition, further research
on the absolute effects of the associations
of oral contraceptive use with breast and
ovarian cancer weighted with the current
practice of risk-reducing surgery is
needed.
Strengths and limitations
Limitations of retrospective studies in
BRCA1/2 mutation carriers include the
potential testing and survival biases
because of the inclusion of prevalent
cases. BRCA1 and BRCA2 mutation
carriers tested in clinics were not
randomly sampled with respect to their
disease status. Generally, the first
woman in the family who is tested has a
personal history of breast or ovarian
cancer. Most carriers were selected from
high-risk families qualifying for genetic
testing, resulting in an oversampling of
women with breast and ovarian cancer.
To correct for the potential testing bias,
we used the extended weighted
approach developed by Antoniou
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et al,8,9 in which women were differen-
tially weighted according to whether
they had breast or ovarian cancer or
were unaffected, to ensure that age-
specific incidence rates implied by the
weighted cohort were consistent with
known incidence rates for BRCA1 and
BRCA2 mutation carriers. Because
reliable weight calculations were
impossible to obtain because of the
subgroup sample size, subanalyses on
birth cohort and study were un-
weighted. However, the results of un-
weighted analyses were informative,
giving a direction for further research.
Survival bias might occur if oral con-
traceptive use is associated with survival
after ovarian cancer diagnosis. Studies in
the general population have suggested
that oral contraceptive use before a
diagnosis of ovarian cancer is associated
with better outcomes.12,17e21 A meta-
analysis has shown that the greatest dif-
ference in survival was associated with
duration of use of oral contraceptives of
over 5 years within the last 20 years of
use.19 However, studies of BRCA1 and
BRCA2 mutation carriers are
lacking.22e24 If oral contraceptive use
has a similar effect on ovarian cancer
survival in BRCA1 and BRCA2mutation
carriers, HR estimates based on retro-
spective studies would be biased toward
the null hypothesis of no association.
Consistent with the results of our left-
truncated analysis, associations between
oral contraceptive use and ovarian can-
cer risk were somewhat stronger than the
associations in the full-retrospective an-
alyses for both BRCA1 and BRCA2 mu-
tation carriers. Because the prognosis of
ovarian cancer might be poor, a left
truncation at 3 years would be even
better. However, the number of ovarian
cancer cases would drop from 346 to 245
for BRCA1 and from 106 to 64 for
BRCA2.
Data on specific oral contraceptive
formulation used were not available.
Analyses stratified on calendar year of
starting oral contraceptive use (HR esti-
mates varied between 0.45 and 0.73)
(Table 1) and study or country (HR es-
timates varied between 0.43 and 0.82)
have shown comparable HRs among
strata, with overlapping CIs.
A prospective analysis based on incident
ovarian cancer cases after DNA testing
would, in principle, eliminate testing and
survival bias completely. However, such
studies are challenging given the high up-
take of RRSO after genetic testing. This
results in a short duration of prospective
follow-up and increased chance of infor-
mative censoring.
Conclusions
For BRCA1 mutation carriers, oral con-
traceptive use was associated with a
reduction in ovarian cancer risk. The
risk was more strongly reduced with
longer durations of oral contraceptive
use, and risk reductions persisted for a
long period. The findings for BRCA2
mutation carriers were similar, but
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SUPPLEMENTAL TABLE 1
The association between oral contraceptive use and risk of ovarian cancer, by attained age for 3989 BRCA1 mutation carriers
Variable
Attained age of <50 y (n¼3268) Attained age of >50 y (n¼958)
OvCaþ, n (%)a OvCa, n (%)a HR (95% CI)b,c OvCaþ, n (%)c OvCa, n (%)c HR (95% CI)b,c
n (%) 150 (4.6) 3118 (95.4) 196 (20.5) 762 (79.5)
Mean age at end of
follow-up (SD), y
43.6 (4.6) 37.3 (8.5) 57.9 (5.9) 57.2 (6.3)
Age at end of follow-up, y
<45 77 (51.3) 2402 (77.0) 0 (0.0) 0 (0.0)
45e64 73 (48.7) 716 (23.0) 165 (84.2) 663 (87.0)
>65 0 (0.0) 0 (0.0) 31 (15.8) 99 (13.0)
Oral contraceptive use
Never (<6 mo) 50 (34.7) 467 (15.7) 1.00 83 (46.9) 251 (35.9) 1.00
Ever 94 (65.3) 2507 (84.3) 94 (53.1) 448 (64.1) 0.63 (0.43e0.92)
Ever, starting age unknown 0 91 11 41
Missing 6 53 8 22
Total duration of use
Never (<6 mo) 50 (35.7) 467 (16.7) 1.00 83 (49.1) 251 (37.0) 1.00
<5 y 36 (25.7) 524 (18.7) 0.86 (0.52e1.44) 31 (18.3) 135 (19.9) 0.62 (0.38e1.02)
5e9 y 28 (20.0) 800 (28.5) 0.48 (0.27e0.85) 25 (14.8) 119 (17.6) 0.77 (0.45e1.33)
10 y 26 (18.6) 1013 (36.1) 0.27 (0.15e0.49) 30 (17.8) 173 (25.5) 0.52 (0.31e0.86)
Ever, no period specific data 4 261 19 62
Missing 6 53 8 22
Trendd P¼2.8E-04 P¼.471
Data are presented as number (percentage), unless otherwise indicated.
CI, confidence interval; EMBRACE, Epidemiological Study of Familial Breast Cancer; GENEPSO, Gene Etude Prospective Sein Ovaire; HR, hazard ratio; OvCa, ovarian cancer.
a Distribution of variables at end of follow-up; b Weighted: to account for the oversampling of affected individuals (breast and ovarian cancer); c Intrinsically stratified on study (EMBRACE, GENEPSO, other) and birth cohort (1920e1946, 1947e1954, 1955e1980).
Clustered on family membership; d Trend tests were based on the P value of the category-specific mean as a continuous variable of ever oral contraceptive users.
































Characteristics of 4818 BRCA1 and 2844 BRCA2 mutation carriers in the full-retrospective IBCCS
Characteristic
BRCA1 mutation carriers BRCA2 mutation carriers
OvCaþ OvCa OvCaþ OvCa
n¼4818 n¼2844
n (%) 555 (11.5) 4263 (88.5) 174 (6.1) 2670 (93.9)
Mean age at end of follow-up (SD) 50.2 (8.8) 40.6 (11.1) 55.1 (9.4) 43.3 (11.6)
Age at end of follow-up
<37 y 30 (5.4) 1619 (38.0) 7 (4.0) 779 (29.2)
37e46 y 163 (29.4) 1447 (33.9) 22 (12.6) 910 (34.1)
>47 y 362 (65.2) 1197 (28.1) 145 (83.3) 981 (36.7)
Mean person-years (y/person) (SD) 50.2 (8.8) 40.6 (11.1) 55.1 (9.4) 43.3 (11.6)
Censored for
Ovarian cancer 555 (100.0) 0 (0.0) 174 (100.0) 0 (0.0)
DNA test or baseline questionnaire 0 (0.0) 3781 (88.7) 0 (0.0) 2357 (88.3)
Other cancer 0 (0.0) 165 (3.9) 0 (0.0) 127 (4.8)
Bilateral RRSO 0 (0.0) 317 (7.4) 0 (0.0) 186 (7.0)
Year at end of follow-up
1958e1989 68 (12.3) 121 (2.8) 20 (11.5) 86 (3.2)
1990e2000 257 (46.3) 1500 (35.2) 72 (41.4) 554 (20.8)
2001e2005 152 (27.4) 1472 (34.5) 88 (42.9) 1037 (38.8)
2006e2012 78 (14.1) 1170 (27.5) 62 (30.2) 993 (37.2)
Birth year
1920e1941 143 (25.8) 295 (6.9) 79 (45.4) 244 (9.1)
1942e1950 189 (34.1) 579 (13.6) 50 (28.7) 417 (15.6)
1951e1992 223 (40.2) 3389 (79.5) 45 (25.9) 2009 (75.2)
Studya
EMBRACE 187 (12.0) 1373 (88.0) 90 (6.6) 1265 (93.4)
GENEPSO 99 (9.7) 918 (90.3) 23 (3.9) 575 (96.2)
HEBON 61 (7.6) 741 (92.4) 21 (8.9) 216 (91.1)
Otherb 208 (14.5) 1231 (85.6) 40 (6.1) 614 (93.9)
Breast cancer
No 381 (68.7) 2658 (62.4) 127 (73.0) 1685 (63.1)
Yes 174 (31.4) 1605 (37.7) 47 (27.0) 985 (36.9)
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SUPPLEMENTAL TABLE 2
Characteristics of 4818 BRCA1 and 2844 BRCA2 mutation carriers in the full-retrospective IBCCS (continued)
Characteristic
BRCA1 mutation carriers BRCA2 mutation carriers
OvCaþ OvCa OvCaþ OvCa
n¼4818 n¼2844
Number of ovarian cancers among first- and second-
degree relatives
No ovarian cancer 209 (49.6) 2143 (63.4) 86 (66.7) 1571 (78.4)
1 148 (35.2) 884 (26.1) 31 (24.0) 343 (17.1)
2 64 (15.2) 355 (10.5) 12 (9.3) 89 (4.4)
Missing 133 880 44 667
Cancer type unknown 1 1 1 0
Data are presented as number (percentage), unless otherwise indicated.
BRCA, breast cancer; CNIO, Spanish National Cancer Center; DKFZ, German Consortium for Translational Cancer Research; EMBRACE, Epidemiological Study of Familial Breast Cancer; GC-HBOC,
German Consortium of Hereditary Breast and Ovarian Cancer; GENEPSO, Gene Etude Prospective Sein Ovaire; HCSC, Health Care Service Corporation; HEBON, Hereditary Breast and Ovarian Cancer
Research Group Netherlands; HSP, Henoch-Schönlein purpura; IBCCS, International BRCA1/2 Carrier Cohort Study; IHCC, International Hereditary Cancer Center; INHERIT, INterdisciplinary HEalth
Research International Team on BReast CAncer susceptibility; MODSQUAD, Modifier Study of Quantitative Effects on Disease; MUV, Medical University of Vienna; NIO, National Institute of
Oceanography; OUH, Oxford University Hospitals; OvCa, ovarian cancer; RRSO, risk-reducing salpingo-oophorectomy; SD, standard deviation.
a The IBCCS is a collaboration of EMBRACE, GENEPSO, HEBON, and other studies; b Other studies included the following: MUV, MODSQUAD, GC-HBOC, Lund-BRCA, OUH, HCSC, INHERIT, NIO, IHCC,
CNIO, Stockholm-BRCA, Milan Italy, HSP, DKFZ, and Dusseldorf Germany, Belgium (order is based on number of carriers included in the analyses).
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SUPPLEMENTAL TABLE 3
The association between aspects of oral contraceptive use and risk of ovarian cancer for 4818 BRCA1 and 2844 BRCA2 mutation carriers in the full-
retrospective cohort
Variable
BRCA1 mutation carriers BRCA2 mutation carriers
OvCaþ, n (%)a OvCa, n (%)a
Weighted,b,c




Never (<6 mo) 235 (46.4) 793 (19.7) 1.00 85 (52.8) 513 (20.4) 1.00
Ever 272 (53.7) 3235 (80.3) 0.64 (0.50e0.81) 76 (47.2) 1997 (79.6) 0.66 (0.43e1.00)
Ever, starting age unknown 19 153 7 104
Missing 29 82 6 56
Calendar year at start
Never (<6 mo) 235 (46.4) 793 (19.7) 1.00 85 (52.8) 513 (20.4) 1.00
1975 182 (35.9) 909 (22.6) 0.57 (0.44e0.75) 60 (37.3) 621 (24.7) 0.69 (0.45e1.07)
>1975 90 (17.8) 2326 (57.8) 0.77 (0.54e1.09) 16 (9.9) 1376 (54.8) 0.49 (0.25e0.97)
Ever, starting year unknown 19 153 7 104
Missing 29 82 6 56
Total duration of use
Never (<6 mo) 235 (48.3) 793 (20.8) 1.00 85 (53.8) 513 (21.6) 1.00
<5 y 92 (18.9) 692 (18.2) 0.84 (0.61e1.14) 24 (15.2) 470 (19.8) 0.81 (0.46e1.43)
5e9 y 79 (16.2) 1010 (26.5) 0.74 (0.53e1.04) 19 (12.0) 615 (25.9) 0.62 (0.34e1.14)
10 y 81 (16.6) 1316 (34.5) 0.44 (0.31e0.61) 30 (19.0) 779 (32.8) 0.59 (0.35e0.99)
Ever, no period specific data 39 370 10 237
Missing 29 82 6 56
Trende P¼4.6E-04 P¼0.369
Time since last use
Never (<6 mo) 235 (48.3) 793 (20.8) 1.00 85 (53.8) 513 (21.6) 1.00
<10 y 56 (11.5) 1712 (44.9) 0.53 (0.37e0.77) 14 (8.9) 921 (38.8) 0.44 (0.22e0.86)
10e19 y 94 (19.3) 773 (20.3) 0.70 (0.51e0.95) 22 (13.9) 483 (20.3) 0.70 (0.39e1.26)
20 y 102 (20.9) 533 (14.0) 0.73 (0.54e1.00) 37 (23.4) 460 (19.4) 0.76 (0.45e1.26)
Ever, no period specific data 39 370 10 237
Missing 29 82 6 56
Trende P¼.113 P¼.162
































The association between aspects of oral contraceptive use and risk of ovarian cancer for 4818 BRCA1 and 2844 BRCA2 mutation carriers in the full-
retrospective cohort (continued)
Variable
BRCA1 mutation carriers BRCA2 mutation carriers
OvCaþ, n (%)a OvCa, n (%)a
Weighted,b,c




Never (<6 mo) 235 (46.4) 793 (19.7) 1.00 85 (52.8) 513 (20.4) 1.00
19 y 83 (16.4) 2014 (50.0) 0.54 (0.38e0.76) 25 (15.5) 1125 (44.8) 0.92 (0.47e1.80)
20e23 y 86 (17.0) 703 (17.5) 0.68 (0.49e0.95) 17 (10.6) 518 (20.6) 0.55 (0.28e1.07)
>23 y 103 (20.3) 518 (12.9) 0.69 (0.51e0.95) 34 (21.1) 354 (14.1) 0.65 (0.40e1.05)
Ever, starting age unknown 19 153 7 104
Missing 29 82 6 56
Trende P¼.292 P¼.396
BRCA, breast cancer; CI, confidence interval; EMBRACE, Epidemiological Study of Familial Breast Cancer; GENEPSO, Gene Etude Prospective Sein Ovaire; HEBON, Hereditary Breast and Ovarian Cancer Research Group Netherlands; HR, hazard ratio; OvCa, ovarian
cancer.
a Distribution of variables at end of follow-up; b Weighted: to account for the oversampling of affected individuals (breast and ovarian cancer); c Unweighted results: BRCA1 HR, 0.91; 95 CI%, 0.77e1.08; BRCA2 HR, 1.02; 95 CI%, 0.76e1.36. In both unweighted
and weighted analyses, the same characteristics of oral contraceptive use were significantly associated; d Intrinsically stratified on study (EMBRACE, GENEPSO, HEBON, other) and birth cohort (1920e1941, 1942e1950, 1951e1992). Clustered on family
membership; e Trend tests were based on the P value of the category-specific mean as a continuous variable of ever oral contraceptive users.
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